アトピー性皮膚炎市場：製品別、投与方法別、重症度別、患者属性別、流通チャネル別-2025-2030年世界予測

アトピー性皮膚炎市場の2023年の市場規模は197億3,000万米ドルで、2024年には208億3,000万米ドルに成長し、CAGRは5.88%、2030年には294億5,000万米ドルに達すると予測されています。

アトピー性皮膚炎は、ほとんど誤解されている皮膚疾患から、皮膚科学研究や市場分析における焦点へと発展してきました。近年、臨床的認知度の向上と、その根底にある遺伝的・環境的要因の深い理解が相まって、この慢性炎症性疾患をめぐる物語は再構築されました。現代の治療パラダイムは、かゆみや不快感といった身体的症状だけでなく、患者が耐える精神的・社会的負担にも対処するようになっています。この疾患の世界の流行は、革新的な治療法の流入、研究開発への投資、罹患者のQOL向上を目的とした臨床試験の増加につながっています。患者中心のアプローチの重要性は、主要な地域や様々な患者層で認識されており、より的を絞った治療やカスタマイズされた治療プロトコルが生み出されています。この進化は、確実なデータセットと臨床的洞察がヘルスケアプロバイダーと意思決定者に明確な指針を提供した包括的な市場分析によって強調されています。現在の情勢は、新たな治療薬、患者のニーズ、市場力学の相互作用の探求を利害関係者に促し、世界中の何百万人もの人々の転帰の改善と新たな希望を約束する道を切り開こうとしています。

アトピー性皮膚炎市場の変革

アトピー性皮膚炎治療の情勢は、技術の進歩、規制状況の進化、革新的な治療アプローチの急増などにより、大きく変化しています。診断学における飛躍的な進歩や精密医療の登場により、臨床医の診断・治療方法は変化し、早期介入や個別化された治療レジメンが重視されるようになりました。新規治療に対する適応臨床試験や促進経路に対する規制当局の支持はますます強まっており、既存製薬企業と新規参入企業の双方に研究への投資を促す原動力となっています。革新的な機器や従来とは異なる治療法が普及し、従来の薬物療法から光による先進的な治療法まで、治療様式が再構築されつつあります。さらに、遠隔医療やモバイルヘルスアプリケーションを含むヘルスケアのデジタル化の進展により、患者のモニタリングや治療のアドヒアランスが強化され、疾患の進行状況の追跡やリアルタイムでの治療法の調整が容易になっています。新たな科学的証拠によってアトピー性皮膚炎に対する理解が深まるにつれ、市場参入企業は戦略を見直し、新たな情報や技術的混乱に迅速に対応できる柔軟なモデルを優先するようになっています。このようなダイナミックな状況は、臨床の進歩にとってエキサイティングな時代であるだけでなく、市場の成長と患者の転帰の改善にとって大きなチャンスでもあります。

主なセグメンテーションの洞察

セグメンテーションを深掘りすることで、アトピー性皮膚炎治療と市場戦略の将来を形作る重要な洞察が明らかになります。製品別分析によると、市場は主に光治療と薬物治療に分化しています。光治療は、エキシマレーザー療法、PUVA療法、UVB療法を含む厳密な研究が行われており、それぞれが異なる有効性と安全性プロファイルを提示しています。同様に、薬物療法は、抗生物質、抗ウイルス剤、抗真菌剤、抗ヒスタミン剤、コルチコステロイド、ヤヌスキナーゼ（JAK）阻害剤、モノクローナル抗体、ピメクロリムスやタクロリムスのような免疫調節剤などのカテゴリーに分類され、多様な患者のニーズに合った幅広い治療オプションを提供しています。製品のセグメンテーションだけでなく、投与方法による評価も、もう一つの洞察の層となります。経口投与は、カプセルや錠剤の観点から慎重に検討され、筋肉内投与や静脈内投与などの非経口投与、クリーム、ローション、軟膏などの局所投与によって補完されます。アトピー性皮膚炎の重症度は、軽度、中等度、重度の3段階に分けられます。患者の属性は成人集団と小児集団に分かれており、年齢特有の課題と期待に対応した個別化された介入の必要性を示しています。最後に、病院薬局、オンライン薬局、小売薬局などの流通チャネルの役割を理解することは、市場へのアクセスや患者へのリーチを最適化するのに役立ちます。セグメンテーションのこれらの層が相互に関連することで、現在の市場力学を包括的に理解することができ、治療の的確なターゲティングとより効果的な資源配分が可能になります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 皮膚疾患やアレルギーの世界の増加により、アトピー性皮膚炎ソリューションの需要が高まっています。
    • 患者の意識の高まりと個別化治療のニーズ
  • 抑制要因
    • アトピー性皮膚炎治療製品の製品リコールに関連する問題
  • 機会
    • 新規非ステロイド治療ソリューションの開発
    • 在宅治療のためのポータブル光線療法機器の革新の高まり
  • 課題
    • アトピー性皮膚炎治療に伴う副作用の懸念の高まり
• 市場セグメンテーション分析
  • 製品：腫れ、赤み、かゆみを軽減するコルチコステロイドの大きな利点
  • 投与方法：使いやすさと患者の順守性により経口投与モードの採用が急増
  • 重症度レベル：中等度の症状の治療における薬物使用の増加
  • 患者の人口統計：成人における症状の迅速な緩和と長期的な症状の効果的な管理を目的としたアトピー性皮膚炎治療の需要が高まっています
  • 流通チャネル：自宅にいながらにして薬を入手するためにオンライン薬局が好まれる傾向が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 アトピー性皮膚炎市場：製品別

• 光療法
  • エキシマレーザー療法
  • PUVA療法
  • UVB療法
• 薬物治療
  • 抗生物質、抗ウイルス薬、抗真菌薬
  • 抗ヒスタミン薬
  • コルチコステロイド
  • ヤヌスキナーゼ（JAK）阻害剤
  • モノクローナル抗体
  • ピメクロリムスまたはタクロリムス

第7章 アトピー性皮膚炎市場投与方法別

• 経口投与
  • カプセル
  • タブレット
• 非経口投与
  • 筋肉内
  • 静脈内
• 局所投与
  • クリーム
  • ローション
  • 軟膏

第8章 アトピー性皮膚炎市場重症度レベル別

• マイルドなアトピー性皮膚炎
• 中程度のアトピー性皮膚炎
• 重度のアトピー性皮膚炎

第9章 アトピー性皮膚炎市場患者の人口統計別

• 成人患者
• 小児患者

第10章 アトピー性皮膚炎市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカのアトピー性皮膚炎市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のアトピー性皮膚炎市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのアトピー性皮膚炎市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Biofrontera AG
• Bristol-Myers Squibb Company
• Chugai Pharmaceutical Co., Ltd.
• Daavlin Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Galderma Holding SA
• GlaxoSmithKline PLC
• Incyte Corporation
• Johnson & Johnson Services Inc.
• LEO Pharma A/S
• Maruho Co., Ltd
• Novartis AG
• Perrigo Company PLC
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc
• Sanofi SA
• Solarc Systems Inc.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. ATOPIC DERMATITIS MARKET MULTI-CURRENCY
• FIGURE 2. ATOPIC DERMATITIS MARKET MULTI-LANGUAGE
• FIGURE 3. ATOPIC DERMATITIS MARKET RESEARCH PROCESS
• FIGURE 4. ATOPIC DERMATITIS MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ATOPIC DERMATITIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ATOPIC DERMATITIS MARKET DYNAMICS
• TABLE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. CANADA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. CANADA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 79. CANADA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 80. CANADA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. CANADA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. CANADA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. CANADA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. CANADA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 85. CANADA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 86. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. CHINA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. CHINA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 131. CHINA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 132. CHINA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. CHINA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. CHINA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. CHINA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. CHINA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 137. CHINA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 138. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. INDIA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. INDIA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 141. INDIA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 142. INDIA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. INDIA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. INDIA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. INDIA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. INDIA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 147. INDIA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 148. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 298. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 308. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 310. ITALY ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 311. ITALY ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 312. ITALY ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 313. ITALY ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 314. ITALY ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 315. ITALY ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 316. ITALY ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 317. ITALY ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 318. ITALY ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 319. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 320. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 321. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 322. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 323. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 324. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 325. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 326. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 327. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2030 (USD MILLION)
• TABLE 328. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 329. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 330. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 331. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2030 (USD MILLION)
• TABLE 332. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 333. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 334. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 335. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 336. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 337. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-

The Atopic Dermatitis Market was valued at USD 19.73 billion in 2023 and is projected to grow to USD 20.83 billion in 2024, with a CAGR of 5.88%, reaching USD 29.45 billion by 2030.

Atopic dermatitis has evolved from being a largely misunderstood skin condition to a focal point in dermatological research and market analytics. In recent years, increasing clinical awareness, combined with a deeper understanding of the underlying genetic and environmental factors, has reshaped the narrative around this chronic inflammatory disorder. Modern treatment paradigms now address not only physical symptoms such as itch and discomfort, but also the emotional and social burdens that patients endure. The rising global prevalence of the condition has led to an influx of innovative treatment modalities, investment in research and development, and an increasing number of clinical trials aimed at enhancing quality of life for those affected. The importance of patient-centric approaches has been recognized across key regions and various patient demographics, resulting in more targeted therapies and customized treatment protocols. This evolution is underscored by comprehensive market analysis where robust datasets and clinical insights have provided clearer guidance for healthcare providers and decision makers. The current landscape invites stakeholders to explore the interplay between emerging therapeutics, patient needs, and market dynamics, forging a path that promises improved outcomes and renewed hope for millions of individuals worldwide.

Transformative Shifts in the Atopic Dermatitis Landscape

The landscape of atopic dermatitis management has undergone transformative shifts, driven by technological advancements, evolving regulatory frameworks, and a surge in innovative therapeutic approaches. Breakthroughs in diagnostics and the advent of precision medicine have altered how clinicians diagnose and treat the condition, emphasizing early intervention and personalized treatment regimens. Regulatory bodies are increasingly supportive of adaptive clinical trials and accelerated pathways for novel therapies, providing the impetus for both established pharmaceutical companies and new entrants to invest in research. Innovative devices and non-traditional treatment options are gaining traction, reshaping treatment modalities that extend from conventional pharmacotherapy to advanced light-based interventions. Additionally, growing digitalization in healthcare-including telemedicine and mobile health applications-has enhanced patient monitoring and therapy adherence, making it easier to track the progression of the disease and adjust treatments in real time. As emerging scientific evidence continues to refine our understanding of atopic dermatitis, market participants are now rethinking their strategies, prioritizing flexible models that can rapidly adapt to new information and technological disruptions. This dynamic landscape signals not only exciting times for clinical advancements but also presents significant opportunities for market growth and improved patient outcomes.

Key Segmentation Insights

A deep dive into segmentation reveals crucial insights that are shaping the future of atopic dermatitis treatment and market strategies. Analysis by product shows that the market is primarily differentiated into light therapy and medication applications. Light therapy has seen rigorous studies encompassing Excimer Laser Therapy, PUVA Therapy, and UVB Therapy, each presenting distinct efficacy and safety profiles. Similarly, medications have been dissected into categories such as antibiotics, antivirals or antifungals, antihistamines, corticosteroids, Janus Kinase (JAK) inhibitors, monoclonal antibodies, and immunomodulators like pimecrolimus or tacrolimus, offering a wide spectrum of therapeutic options to suit diverse patient needs. Beyond product segmentation, an evaluation by mode of administration adds another layer of insight. Oral administration, carefully considered in terms of capsules and tablets, is complemented by parenteral routes, including both intramuscular and intravenous procedures, as well as topical applications in the form of creams, lotions, and ointments. Consideration of severity levels-ranging from mild, moderate, to severe atopic dermatitis-provides a nuanced approach in aligning treatments with clinical presentations. Patient demographics, split between adult and pediatric populations, illustrate the need for tailored interventions that address age-specific challenges and expectations. Lastly, understanding the role of distribution channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, helps in optimizing market access and patient reach. These interconnected layers of segmentation allow for a comprehensive understanding of current market dynamics, enabling precise targeting of therapies and more effective resource allocation.

Based on Product, market is studied across Light Therapy and Medication. The Light Therapy is further studied across Excimer Laser Therapy, PUVA Therapy, and UVB Therapy. The Medication is further studied across Antibiotics, Antivirals or Antifungals, Antihistamines, Corticosteroid, Janus Kinase (JAK) Inhibitors, Monoclonal Antibodies, and Pimecrolimus or Tacrolimus.

Based on Mode Of Administration, market is studied across Oral Administration, Parenteral Administration, and Topical Administration. The Oral Administration is further studied across Capsules and Tablets. The Parenteral Administration is further studied across Intramuscular and Intravenous. The Topical Administration is further studied across Cream, Lotion, and Ointment.

Based on Severity Level, market is studied across Mild Atopic Dermatitis, Moderate Atopic Dermatitis, and Severe Atopic Dermatitis.

Based on Patient Demographics, market is studied across Adult Patients and Pediatric Patients.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Market Dynamics

A thorough regional analysis indicates that market trends are distinctly influenced by geographic distinctions. In the Americas, strong infrastructure and high healthcare spending support advanced therapeutic implementation and robust clinical research environments. Within Europe, the Middle East, and Africa, evolving economic landscapes and shifting regulatory environments have spurred innovation, while enhanced access to modern therapeutics in these regions is gradually aligning with global standards. The Asia-Pacific region stands out due to its rapidly growing economies, expanding patient populations, and increasing awareness of chronic conditions. Advancements in healthcare infrastructure and ongoing investments in research and development are positioning this region as a key player in driving technological innovations and improved patient outcomes in the field of atopic dermatitis.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

In the corporate arena, several leading players are proactively shaping the future of atopic dermatitis treatment through strategic research and robust product pipelines. Innovators such as AbbVie Inc. and Amgen Inc. consistently drive breakthroughs, while companies like AstraZeneca PLC and Bausch Health Companies Inc. have harnessed the power of cross-disciplinary collaborations to push the boundaries of conventional therapies. Biofrontera AG and Bristol-Myers Squibb Company have demonstrated significant commitment by investing in advanced clinical trials, and firms such as Chugai Pharmaceutical Co., Ltd. and Daavlin Company have strategically positioned themselves within niche therapeutic segments. Esteemed industry giants including Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Galderma Holding SA continue to set high benchmarks for clinical efficacy, while GlaxoSmithKline PLC and Incyte Corporation further diversify the market with emerging therapeutic modalities. Johnson & Johnson Services Inc., LEO Pharma A/S, and Maruho Co., Ltd are leveraging their longstanding expertise to refine treatment protocols. Novartis AG, Perrigo Company PLC, Pfizer, Inc., and Regeneron Pharmaceuticals, Inc have adeptly responded to shifting market demands, while industry leaders from Sanofi SA, Solarc Systems Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., and Viatris Inc. complete a competitive landscape that is characterized by continual innovation and steadfast commitment to patient care.

The report delves into recent significant developments in the Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bausch Health Companies Inc., Biofrontera AG, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Daavlin Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma Holding SA, GlaxoSmithKline PLC, Incyte Corporation, Johnson & Johnson Services Inc., LEO Pharma A/S, Maruho Co., Ltd, Novartis AG, Perrigo Company PLC, Pfizer, Inc., Regeneron Pharmaceuticals, Inc, Sanofi SA, Solarc Systems Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., and Viatris Inc.. Actionable Recommendations for Industry Leaders

For industry leaders seeking to navigate and excel within the rapidly evolving atopic dermatitis market, several actionable recommendations emerge from the current data and market trends. First, it is imperative to invest in robust, data-driven research that not only examines traditional therapeutic options but also explores novel treatment modalities. Marketers should consider bolstering their capabilities in digital health technology, integrating telehealth platforms with advanced analytics to understand patient behavior in real time and facilitate personalized care plans. Embracing collaborations with academic institutions and clinical research organizations can further streamline the development of innovative clinical trials and fast-track the introduction of new therapies to the market. Additionally, aligning product development with precise segmentation-considering factors like mode of administration, product type, patient severity levels, and distinct demographic needs-can significantly enhance market penetration and optimize therapeutic outcomes. Leaders are also advised to fortify their distribution channels by leveraging partnerships with hospital, online, and retail pharmacies, ensuring maximum accessibility and timely delivery of treatments. Lastly, a proactive engagement with regulatory bodies through transparent communication and active participation in shaping health policies will not only facilitate quicker market approvals but also build strong credibility among stakeholders. These strategic recommendations are designed to help industry leaders create more tailored and impactful solutions that meet evolving patient demands and drive market growth.

Conclusion: Summing Up Key Findings

In conclusion, the atopic dermatitis market is experiencing a period of unprecedented transformation. Recent advances in treatment modalities, combined with evolving patient demographics and the integration of cutting-edge technology, have fundamentally shifted market dynamics. The nuanced analysis of product segmentation, including comprehensive studies across light therapy and medication strategies, highlights an industry that is poised for continued innovation. Regional trends further underscore the importance of localized strategies as emerging economies and developed markets alike adapt to new clinical realities. Key corporate players are not only investing heavily in research and clinical development but are also redefining their portfolios to meet complex patient needs. As the collective insights from cutting-edge research, advanced product segmentation, and dynamic regional analysis converge, stakeholders can confidently anticipate a future marked by enhanced patient outcomes and robust market growth. The ongoing evolution in treatment interventions and strategic market maneuvers presents a timely opportunity for industry authorities to secure a competitive advantage by aligning their strategies with emerging global trends.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of skin conditions and allergies globally boosts the demand for atopic dermatitis solutions
    • 5.1.1.2. Rising patient awareness and need for personalized therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with product recall in atopic dermatitis treatment products
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel non-steroidal therapeutic solutions
    • 5.1.3.2. Rising innovations in portable phototherapy devices for home-based atopic dermatitis treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Rising side effects concerns associated with atopic dermatitis treatment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Significant benefits of corticosteroid to reduce swelling, redness, and itching
  • 5.2.2. Mode Of Administration: Proliferating adoption of oral administration mode due to ease of use and patient compliance
  • 5.2.3. Severity Level: Increasing usage of medication for the treatment of moderate atopic dermatitis
  • 5.2.4. Patient Demographics: Rising demand of atopic dermatitis treatment in adults for rapid symptom relief & to manage long-term symptoms effectively
  • 5.2.5. Distribution Channel: Growing preference for online pharmacies for acquiring medications from the comfort of their homes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Atopic Dermatitis Market, by Product

• 6.1. Introduction
• 6.2. Light Therapy
  • 6.2.1. Excimer Laser Therapy
  • 6.2.2. PUVA Therapy
  • 6.2.3. UVB Therapy
• 6.3. Medication
  • 6.3.1. Antibiotics, Antivirals or Antifungals
  • 6.3.2. Antihistamines
  • 6.3.3. Corticosteroid
  • 6.3.4. Janus Kinase (JAK) Inhibitors
  • 6.3.5. Monoclonal Antibodies
  • 6.3.6. Pimecrolimus or Tacrolimus

7. Atopic Dermatitis Market, by Mode Of Administration

• 7.1. Introduction
• 7.2. Oral Administration
  • 7.2.1. Capsules
  • 7.2.2. Tablets
• 7.3. Parenteral Administration
  • 7.3.1. Intramuscular
  • 7.3.2. Intravenous
• 7.4. Topical Administration
  • 7.4.1. Cream
  • 7.4.2. Lotion
  • 7.4.3. Ointment

8. Atopic Dermatitis Market, by Severity Level

• 8.1. Introduction
• 8.2. Mild Atopic Dermatitis
• 8.3. Moderate Atopic Dermatitis
• 8.4. Severe Atopic Dermatitis

9. Atopic Dermatitis Market, by Patient Demographics

• 9.1. Introduction
• 9.2. Adult Patients
• 9.3. Pediatric Patients

10. Atopic Dermatitis Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Atopic Dermatitis Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Atopic Dermatitis Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Atopic Dermatitis Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Evommune secures USD 115 million Series C for advancement in chronic inflammatory disease therapies
  • 14.3.2. Organon enhances dermatology portfolio with strategic acquisition of dermavant and VTAMA Cream
  • 14.3.3. FDA approves Eli Lilly EBGLYSS for moderate to severe atopic dermatitis treatment
  • 14.3.4. Biofrontera and LEO Pharma entered an agreement to enhance dermatological treatments in Germany
  • 14.3.5. Arcutis Biotherapeutics launches ZORYVE cream for atopic dermatitis treatment
  • 14.3.6. Dermavant secures Japanese approval for tapinarof in psoriasis and atopic dermatitis
  • 14.3.7. Johnson & Johnson acquires Proteologix to enhance atopic dermatitis treatment portfolio
  • 14.3.8. Almirall partners with CRG to advance atopic dermatitis treatment research
  • 14.3.9. Glenmark and Pfizer collaborate to launch abrocitinib for atopic dermatitis in India
  • 14.3.10. Teva and Biolojic Design entered an agreement to develop innovative antibody therapy for atopic dermatitis and asthma
  • 14.3.11. IMIDomics and Bristol Myers Squibb expand partnership to advance atopic dermatitis research
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Eli Lilly and Company
  • 14.4.2. Pfizer Inc.
  • 14.4.3. Johnson & Johnson Services Inc.
  • 14.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. AstraZeneca PLC
• 4. Bausch Health Companies Inc.
• 5. Biofrontera AG
• 6. Bristol-Myers Squibb Company
• 7. Chugai Pharmaceutical Co., Ltd.
• 8. Daavlin Company
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche Ltd.
• 11. Galderma Holding SA
• 12. GlaxoSmithKline PLC
• 13. Incyte Corporation
• 14. Johnson & Johnson Services Inc.
• 15. LEO Pharma A/S
• 16. Maruho Co., Ltd
• 17. Novartis AG
• 18. Perrigo Company PLC
• 19. Pfizer, Inc.
• 20. Regeneron Pharmaceuticals, Inc
• 21. Sanofi SA
• 22. Solarc Systems Inc.
• 23. Teva Pharmaceutical Industries Ltd.
• 24. UCB S.A.
• 25. Viatris Inc.